Supreme Court nominee issued three decisions on Hatch-Waxman regime as district court judge, including case in which she ruled against the FDA’s denial of orphan drug designation and another in which she deferred to the agency’s view on exclusivity. Her analysis of facts may play a role if the court takes up a case on administrative agency deference.

Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.

Arthrex reportedly paid a physician to use the company’s orthopedic products. Separately, multiple telehealth-related false-billing schemes landed six men in hot water.

A new Informa Meddevicetracker report outlines projections for the fracture fixation devices market.